ABL1 and acute lymphoblastic leukemia: However, the complexity and cost of such an approach would first require a more in depth study of whether BCR–ABL1 mutations are a substantial contributor to resistance and relapse in Ph+ ALL treated with intensive chemotherapy plus TKI.